Carter Worth takes a look at the charts for mid-cap biotech Immunovant.
Get this delivered to your inbox, and more info about our products and services.
Carter Worth breaks down the charts on this biotech stock.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
Frank Cappelleri of CappThesis breaks down the bullish technical backdrop for this pharma-related stock.
David Keller breaks down the technicals on this biotech giant.
The investment bank upgraded the pharma stock to overweight from equal weight.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
